Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor
/PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, small molecule therapeutics for highly aggressive cancers,...
United States Gautam Borthukar Division Of Cancer Medicine American Society Of Hematology Department Of Leukemia Md Anderson Cancer Center
Source: prnewswire.com